| The Relationship Between GLUT-1 and Vascular Endothelial Growth Factor Expression and 18F-FDG Uptake in Esophageal Squamous Cell Cancer Patients. | |
| | |
MedLine Citation:
|
PMID: 22475893 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE:: To examine the relationship between glucose transporter-1 (GLUT-1) and vascular endothelial growth factor (VEGF) expression and F-FDG uptake in esophageal squamous cell cancer patients. MATERIALS AND METHODS:: Fifty-seven patients (52 male and 5 female) were included in this study. F-FDG PET/CT was performed prior to the surgery. Immunohistochemistry was performed using postoperative histopathological specimens. The estimation of immunohistochemistry was conducted using scoring analysis. We investigated the correlations between maximum standardized uptake value (SUVmax) and GLUT-1/VEGF expressions/pathologic tumor length (p-tumor length), and the relationships between pathologic T (p-T) stage and GLUT-1/VEGF expressions/SUVmax and between lymph node metastasis (p-N) stage and GLUT-1/VEGF expressions/SUVmax. RESULTS:: SUVmax significantly correlated with GLUT-1 expressions and p-tumor length (GLUT-1: r = 0.475, P < 0.001; p-tumor length: r = 0.475, P < 0.001). SUVmax of the primary tumor had a significant relationship with p-T stage, p-N stage, and VEGF expression (p-T stage: P < 0.001; p-N stage: P = 0.037; VEGF expression: P = 0.009). There was a statistically significant difference between GLUT-1 expression and p-T stage/VEGF expression, but not p-N stage (p-T stage: P = 0.012; VEGF expression: P = 0.01; p-N stage: P = 0.572). VEGF expression had a significant relationship with p-T stage, but not with p-N stage (p-T stage: P = 0.032; p-N stage: P = 0.763). CONCLUSION:: F-FDG uptake can be determined by GLUT-1 and VEGF. SUVmax would have a connection with the tumor progression and lymph node metastasis. |
| | |
Authors:
|
Maiko Kobayashi; Hayato Kaida; Akihiko Kawahara; Satoshi Hattori; Seiji Kurata; Masanobu Hayakawa; Yasumitsu Hirose; Masafumi Uchida; Masayoshi Kage; Hiromasa Fujita; Naofumi Hayabuchi; Masatoshi Ishibashi |
Related Documents
:
|
22533343 - Idh1 is downregulated during early skin tumorigenesis which can be inhibited by overexp... 17020983 - Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implic... 15781323 - Emmprin/cd147, an mmp modulator in cancer, development and tissue repair. |
Publication Detail:
|
Type: JOURNAL ARTICLE |
Journal Detail:
|
Title: Clinical nuclear medicine Volume: 37 ISSN: 1536-0229 ISO Abbreviation: - Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-4-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7611109 Medline TA: Clin Nucl Med Country: - |
Other Details:
|
Languages: ENG Pagination: 447-452 Citation Subset: - |
Affiliation:
|
From the *Division of Nuclear Medicine, PET Center, and Department of Radiology, Kurume University School of Medicine, Kurume City, Fukuoka, Japan; †Department of Diagnostic Pathology, Kurume University Hospital, Kurume University School of Medicine, Kurume City, Fukuoka, Japan; ‡Biostatistics Center, Kurume University School of Medicine, Kurume City, Fukuoka, Japan; and §Department of Surgery, Kurume University School of Medicine, Kurume University School of Medicine, Kurume City, Fukuoka, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predictive Value of Metabolic Tumor Volume Measured by 18F-FDG PET for Regional Lymph Node Status in...
Next Document: 18F-FDG PET/CT and Contrast-Enhanced CT in a One-Stop Diagnostic Procedure: A Better Strategy for Ma...